We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+66.43%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$489M
AUM Growth
-$16.5M
(-3.3%)
Cap. Flow
-$88.1M
Cap. Flow
% of AUM
-18.03%
Top 10 Holdings %
Top 10 Hldgs %
36.36%
Holding
114
New
25
Increased
12
Reduced
45
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPRB
Spruce Biosciences
SPRB
|
+$14.1M |
| 2 |
AstraZeneca
AZN
|
+$13.9M |
| 3 |
Sanofi
SNY
|
+$10.9M |
| 4 |
Universal Health Services
UHS
|
+$10.1M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$9.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$17M |
| 2 |
McKesson
MCK
|
+$11.8M |
| 3 |
Molina Healthcare
MOH
|
+$9.7M |
| 4 |
AMN Healthcare
AMN
|
+$9.23M |
| 5 |
Cardinal Health
CAH
|
+$8.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.67% |
| 2 | Technology | 1.08% |
| 3 | Consumer Staples | 0.76% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Orthofix Medical
OFIX
$421M
| $5.95M | 1.22% |
138,525
-79,392
| -36% | -$2.9M |
|
27
United Therapeutics
UTHR
$22B
| $5.88M | 1.2% |
38,734
-20,476
| -35% | -$2.69M |
|
|
EFOR
28
Everforth Inc
EFOR
$1.3B
| $5.27M | 1.08% |
+63,077
| New | +$4.85M |
|
|
RDUS
29
DELISTED
Radius Health, Inc.
RDUS
| $5.24M | 1.07% |
293,157
-401,613
| -58% | -$6.03M |
|
|
EPIX
30
DELISTED
ESSA Pharma
EPIX
| $5.17M | 1.06% |
433,023
-223,020
| -34% | -$1.57M |
|
|
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
| $4.92M | 1.01% |
7,398
-4,273
| -37% | -$2.38M |
|
32
Cellectar Biosciences
CLRB
$20.1M
| $4.85M | 0.99% |
7,770
+3,222
| +71% | +$1.48M |
|
33
Ionis Pharmaceuticals
IONS
$9.01B
| $4.58M | 0.94% |
+81,026
| New | +$4.04M |
|
34
Ardelyx
ARDX
$1.21B
| $4.46M | 0.91% |
689,321
-65,000
| -9% | -$386K |
|
35
Varex Imaging
VREX
$522M
| $4.45M | 0.91% |
266,740
+151,346
| +131% | +$2.26M |
|
|
ARNA
36
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.44M | 0.91% |
57,738
-14,015
| -20% | -$1.05M |
|
|
SYNH
37
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $4.43M | 0.91% |
65,000
-46,285
| -42% | -$2.89M |
|
38
Kura Oncology
KURA
$817M
| $4.32M | 0.88% |
132,283
+101,000
| +323% | +$3.55M |
|
|
CCRN
39
DELISTED
Cross Country Healthcare
CCRN
| $4.3M | 0.88% |
485,164
+83,929
| +21% | +$683K |
|
|
CHAQ.U
40
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
| $4.24M | 0.87% |
400,000
| – | – |
|
41
Larimar Therapeutics
LRMR
$426M
| $4.04M | 0.83% |
188,661
-111,930
| -37% | -$2.24M |
|
|
42
Molina Healthcare
MOH
$10.2B
| $3.99M | 0.82% |
18,763
-47,011
| -71% | -$9.7M |
|
|
GWPH
43
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.9M | 0.8% |
33,801
+13,300
| +65% | +$1.49M |
|
44
Integer Holdings
ITGR
$4.25B
| $3.79M | 0.78% |
46,699
-82,677
| -64% | -$5.8M |
|
45
Syndax Pharmaceuticals
SNDX
$1.78B
| $3.78M | 0.77% |
170,142
+165,346
| +3,448% | +$3.43M |
|
|
NTUS
46
DELISTED
Natus Medical Inc
NTUS
| $3.74M | 0.77% |
186,833
+83,008
| +80% | +$1.63M |
|
47
Herbalife
HLF
$1.31B
| $3.73M | 0.76% |
77,660
-10,940
| -12% | -$528K |
|
48
PUT
Medifast
MED
$137M
| $3.57M | 0.73% |
+18,200
| New | +$3.22M |
|
|
MESO
49
PUT
Mesoblast
MESO
$1.94B
| $3.54M | 0.73% |
208,650
-573,000
| -73% | -$14.1M |
|
50
Viking Therapeutics
VKTX
$3.91B
| $3.43M | 0.7% |
609,780
-100,000
| -14% | -$606K |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sio Capital Management held 114 positions worth $489M, down 3.3% from $505M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management withdrew a net $88.1M in Q4 2020, closing 25 positions and reducing 45 holdings. Its most notable exit was Johnson & Johnson, an estimated $17M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Sio Capital Management opened a new position in Spruce Biosciences worth $15.5M.
- Sio Capital Management's largest Q4 2020 buy was Spruce Biosciences: 8,489 shares worth $15.5M.
- Sio Capital Management added most to Kura Oncology in Q4 2020, an estimated $3.55M increase.
- Sio Capital Management's biggest Q4 2020 reduction was McKesson, cutting an estimated $11.8M.
- Sio Capital Management fully exited Johnson & Johnson in Q4 2020, selling an estimated $17M.
- Sio Capital Management's ten largest holdings make up 36% of its $489M portfolio in Q4 2020.
- Sio Capital Management opened 25 new positions and closed 25 in Q4 2020.
- Sio Capital Management's portfolio value fell 3.3% quarter-over-quarter to $489M.
Based on Sio Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.